PMID- 29738697
OWN - NLM
STAT- MEDLINE
DCOM- 20181002
LR  - 20221207
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 483
DP  - 2018 Aug
TI  - Prognostic and clinical significance of histone deacetylase 1 expression in 
      breast cancer: A meta-analysis.
PG  - 209-215
LID - S0009-8981(18)30214-6 [pii]
LID - 10.1016/j.cca.2018.05.005 [doi]
AB  - BACKGROUND: There are conflicting reports about the role of histone deacetylase 1 
      (HDAC1) in breast cancer prognosis. Here, we conducted a meta-analysis to 
      investigate the prognostic significance of HDAC1 in breast cancer. MATERIALS AND 
      METHODS: We searched different databases to identify studies evaluating the 
      association between HDAC1 expression and its prognostic value in breast cancer. 
      The pooled hazard ratios (HRs) and odds radios (ORs) with 95% confidence 
      intervals (95% CIs) were calculated from these studies to assess specific 
      correlation. RESULTS: Our meta-analysis of four databases identified 7 eligible 
      studies with 1429 total patients. We found that HDAC1 over-expression did not 
      correlate with disease-free survival (DFS) and overall survival (OS) in breast 
      cancer. Subgroup analysis indicated an association between up-regulated HDAC1 
      expression and better OS (HR = 0.47, 95% CI: 0.23-0.97; P = 0.04) in Asian breast 
      cancer patients. However, false-positive report probability (FPRP) analysis and 
      trial sequential analysis (TSA) indicated that the results need further 
      validation. Furthermore, HDAC1 over-expression was associated with positive 
      estrogen receptor (ER) expression (OR, 3.30; 95% CI, 1.11-9.83; P = 0.03) and 
      negative human epidermal growth factor receptor 2 (HER2) expression (OR, 1.79; 
      95% CI, 1.22-2.61; P = 0.003), but there were no significant differences between 
      patients based on age, tumor size, lymph node metastasis, nuclear grade, or 
      progesterone receptor (PR) expression. CONCLUSION: Overall, our meta-analysis 
      demonstrated an association between increased HDAC1 expression and better OS in 
      Asian breast cancer patients. In addition, HDAC1 over-expression correlated with 
      positive ER and negative HER2 expression in breast cancer. However, researches in 
      large patients' randomised controlled trials (RCTs) are needed to confirm the 
      results.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Qiao, Weiqiang
AU  - Qiao W
AD  - Department of Breast Surgery, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Liu, Heyang
AU  - Liu H
AD  - Department of Oncology, The First Affiliated Hospital, and College of Clinical 
      Medicine of Henan University of Science and Technology, Luoyang 471003, China.
FAU - Liu, Ruidong
AU  - Liu R
AD  - Department of Breast Surgery, The First Affiliated Hospital of Henan University 
      of Traditional Chinese Medicine, Zhengzhou 450000, China.
FAU - Liu, Qipeng
AU  - Liu Q
AD  - Department of Breast Surgery, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Breast Surgery, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Guo, Wanying
AU  - Guo W
AD  - Department of Breast Surgery, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Li, Peng
AU  - Li P
AD  - Department of Breast Surgery, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China.
FAU - Deng, Miao
AU  - Deng M
AD  - Department of Breast Surgery, The First Affiliated Hospital, and College of 
      Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, 
      China. Electronic address: dengmiao1973@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20180505
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.5.1.98 (Histone Deacetylase 1)
SB  - IM
MH  - Asian People
MH  - Breast Neoplasms/*diagnosis/mortality
MH  - Histone Deacetylase 1/*analysis/metabolism
MH  - Humans
MH  - Odds Ratio
MH  - Prognosis
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Estrogen/analysis
MH  - Survival Analysis
OTO - NOTNLM
OT  - Breast cancer
OT  - HDAC1
OT  - Meta-analysis
OT  - Prognosis
EDAT- 2018/05/09 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/05/09 06:00
PHST- 2018/03/13 00:00 [received]
PHST- 2018/05/03 00:00 [revised]
PHST- 2018/05/04 00:00 [accepted]
PHST- 2018/05/09 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/05/09 06:00 [entrez]
AID - S0009-8981(18)30214-6 [pii]
AID - 10.1016/j.cca.2018.05.005 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2018 Aug;483:209-215. doi: 10.1016/j.cca.2018.05.005. Epub 2018 
      May 5.